The Effect of Potentially Hepatotoxic Medicinal Products on Alanine Transaminase Levels in COVID-19 Patients: A Case–Control Study

DOI record: { "DOI": "10.30895/2312-7821-2025-458", "ISSN": [ "2619-1164", "2312-7821" ], "URL": "http://dx.doi.org/10.30895/2312-7821-2025-458", "abstract": "<jats:p><jats:bold>INTRODUCTION.</jats:bold> Elevated liver enzyme levels are common in patients with COVID-19. Personalised prescribing to reduce the risk of hepatotoxicity requires studying the role of pharmacotherapy in the development of liver dysfunction in COVID-19 patients.</jats:p><jats:p><jats:bold>AIM.</jats:bold> This study aimed to identify the presence and strength of the relationship between an increase in alanine transaminase (ALT) levels and the use of potentially hepatotoxic medicinal products in hospitalised patients with COVID-19 to provide practising clinicians with a case-specific approach for selecting medicinal products with a lower risk of hepatotoxicity.</jats:p><jats:p><jats:bold>MATERIALS AND METHODS.</jats:bold> The authors analysed 1,296 medical records of COVID-19 patients who had been admitted to a Volgograd Region hospital for infectious diseases in 2020–2022. A case-control study was performed using the pair-matched case–control method, with pairs of patients matched by their sex, age, and COVID-19 severity and outcomes. The authors identified the medical records of COVID-19 patients with baseline alanine transaminase (ALT) levels &lt;1 or 2 times the upper limit of the normal range (ULN) and selected the medical records of the patients who had been having elevated ALT levels ≥2, 3, and 5 ULN (cases) or ALT levels &lt;2 ULN (controls) throughout their hospital stay.</jats:p><jats:p><jats:bold>RESULTS.</jats:bold> There was a significantly higher likelihood of detecting the use of ≥3 medicinal products associated with a high risk of drug-induced liver injury (DILI) in the medical records of all case groups than in those of the controls (odds ratio (OR)=2.38 (1.54–3.67), <jats:italic>p</jats:italic>&lt;0.001, for detecting the use of ≥3 high-risk medicinal products and an increase in ALT levels from &lt;1 ULN at baseline to &gt;2 ULN, 195 pairs; OR=2.59 (1.48–4.53), <jats:italic>p</jats:italic>&lt;0.001, for detecting the use of ≥3 high-risk medicinal products and an increase in ALT levels from &lt;1 ULN at baseline to &gt;3 ULN, 115 pairs). Certain medicinal products were associated with a significant increase in the risk of ALT rising to levels &gt;2 ULN in patients with baseline levels &lt;1 ULN (remdesivir: OR=4.38 (2.98–6.42), <jats:italic>p</jats:italic>&lt;0.001; olokizumab: OR=7.83 (3.35–18.32), <jats:italic>p</jats:italic>&lt;0.001; and levilimab: OR=3.0 (1.19–7.56), <jats:italic>p</jats:italic>=0.014) and levels &gt;3 ULN in patients with baseline levels &lt;2 ULN (remdesivir: OR=2.0 (1.21–3.30), <jats:italic>p</jats:italic>=0.006; olokizumab: OR=3.94 (2.35–6.62), <jats:italic>p</jats:italic>&lt;0.001; and levilimab: OR=2.67 (1.24–5.74), <jats:italic>p</jats:italic>=0.009).</jats:p><jats:p><jats:bold>CONCLUSIONS.</jats:bold> According to this study, there is a statistically significant association between elevated ALT levels in hospitalised COVID-19 patients and the use of several hepatotoxic medicines. Further studies are required to assess the safety of medicines used to treat COVID-19. It is also necessary to develop methods for the early detection and prevention of DILI.</jats:p>", "author": [ { "ORCID": "https://orcid.org/0000-0002-0258-4092", "affiliation": [ { "name": "Volgograd State Medical University" } ], "authenticated-orcid": true, "family": "Petrov", "given": "V. I.", "sequence": "first" }, { "ORCID": "https://orcid.org/0000-0002-4778-5015", "affiliation": [ { "name": "Volgograd State Medical University" } ], "authenticated-orcid": true, "family": "Ryazanova", "given": "A. Yu.", "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0002-2578-6228", "affiliation": [ { "name": "Volgograd State Medical University" } ], "authenticated-orcid": true, "family": "Tokareva", "given": "N. S.", "sequence": "additional" } ], "container-title": "Safety and Risk of Pharmacotherapy", "container-title-short": "Bezopasnost' i risk farmakoterapii", "content-domain": { "crossmark-restriction": true, "domain": [ "www.risksafety.ru" ] }, "created": { "date-parts": [ [ 2025, 2, 26 ] ], "date-time": "2025-02-26T13:26:48Z", "timestamp": 1740576408000 }, "deposited": { "date-parts": [ [ 2025, 2, 28 ] ], "date-time": "2025-02-28T12:51:42Z", "timestamp": 1740747102000 }, "indexed": { "date-parts": [ [ 2025, 3, 1 ] ], "date-time": "2025-03-01T05:31:32Z", "timestamp": 1740807092060, "version": "3.38.0" }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2025, 2, 26 ] ] }, "license": [ { "URL": "https://www.risksafety.ru/jour/about/editorialPolicies#openAccessPolicy", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 2, 26 ] ], "date-time": "2025-02-26T00:00:00Z", "timestamp": 1740528000000 } } ], "link": [ { "URL": "https://www.risksafety.ru/jour/article/viewFile/458/1328", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" } ], "member": "12343", "original-title": [], "prefix": "10.30895", "published": { "date-parts": [ [ 2025, 2, 26 ] ] }, "published-online": { "date-parts": [ [ 2025, 2, 26 ] ] }, "publisher": "SCEEMP", "reference": [ { "DOI": "10.1186/s12916-016-0553-2", "doi-asserted-by": "crossref", "key": "ref1", "unstructured": "Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: A systematic review of the world literature. BMC Med. 2016;14:10. https://doi.org/10.1186/s12916-016-0553-2" }, { "DOI": "10.1111/j.1365-2125.2004.02133.x", "doi-asserted-by": "crossref", "key": "ref2", "unstructured": "De Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: A population based case-control study. Br J Clin Pharmacol. 2004;58(1):71–80. https://doi.org/10.1111/j.1365-2125.2004.02133.x" }, { "DOI": "10.1002/hep4.1794", "doi-asserted-by": "crossref", "key": "ref3", "unstructured": "Valenti L, Pelusi S, Bianco C, Ceriotti F, Berzuini A, Iogna Prat L, et al. Definition of healthy ranges for alanine aminotransferase levels: A 2021 update. Hepatol Commun. 2021;5(11):1824–32. https://doi.org/10.1002/hep4.1794" }, { "DOI": "10.1097/MEG.0000000000001225", "doi-asserted-by": "crossref", "key": "ref4", "unstructured": "Schmilovitz-Weiss H, Gingold-Belfer R, Boltin D, Beloosesky Y, Meyerovitch J, Tor R, et al. Risk of mortality and level of serum alanine aminotransferase among community-dwelling elderly in Israel. Eur J Gastroenterol Hepatol. 2018;30(12):1428–33. https://doi.org/10.1097/MEG.0000000000001225" }, { "DOI": "10.2147/CLEP.S241292", "doi-asserted-by": "crossref", "key": "ref5", "unstructured": "Jensen MD, Lauritzen T, Vilstrup H, Jepsen P. Alanine aminotransferase and 20-year risk of major chronic diseases and death in a healthy cohort aged 30 to 49 years. Clin Epidemiol. 2020;12:345–51. https://doi.org/10.2147/CLEP.S241292" }, { "DOI": "10.1007/s40264-018-0654-2", "doi-asserted-by": "crossref", "key": "ref6", "unstructured": "Danan G, Teschke R. Drug-induced liver injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch? Drug Saf. 2018;41;735–43. https://doi.org/10.1007/s40264-018-0654-2" }, { "DOI": "10.3390/ijms17010014", "doi-asserted-by": "crossref", "key": "ref7", "unstructured": "Danan G, Teschke R. RUCAM in drug and herb induced liver injury: The update. Int J Mol Sci. 2015;17(1):14. https://doi.org/10.3390/ijms17010014" }, { "DOI": "10.1111/apt.14952", "doi-asserted-by": "crossref", "key": "ref8", "unstructured": "Bessone F, Dirchwolf M, Rodil MA, Razori MV, Roma MG. Review article: Drug-induced liver injury in the context of nonalcoholic fatty liver disease — a physiopathological and clinical integrated view. Aliment Pharmacol Ther. 2018;48(9):892–913. https://doi.org/10.1111/apt.14952" }, { "DOI": "10.1007/s40264-020-01014-2", "doi-asserted-by": "crossref", "key": "ref9", "unstructured": "Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, et al. Consensus guidelines: Best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in adults with chronic viral hepatitis and adults with cirrhosis secondary to hepatitis B, C and nonalcoholic steatohepatitis. Drug Saf. 2021;44(2):133–65. https://doi.org/10.1007/s40264-020-01014-2" }, { "DOI": "10.17116/dokgastro20231203151", "doi-asserted-by": "crossref", "key": "ref10", "unstructured": "Zharova ME, Ivanikov IO, Grigorieva YuV, Nikonov EL. Liver injury in COVID-19: Clinical features and risk factors. Russian Journal of Evidencebased Gastroenterology/ 2023;12(3):51–62 (In Russ.). https://doi.org/10.17116/dokgastro20231203151" }, { "DOI": "10.19163/1994-9480-2020-4(76)-9-15", "doi-asserted-by": "crossref", "key": "ref11", "unstructured": "Petrov VI, Ponomareva AV, Ivakhnenko IV, Razvalyaeva OV, Meshrqi BA, Statsenko VI. Etiopathogenetic aspects of liver injury in patients with COVID-19. Journal of Volgograd State Medical University. 2020;17(4):9–15 (In Russ.). https://doi.org/10.19163/1994-9480-2020-4(76)-9-15" }, { "DOI": "10.3748/wjg.v29.i2.257", "doi-asserted-by": "crossref", "key": "ref12", "unstructured": "Papagiouvanni I, Kotoulas SC, Pataka A, Spyratos DG, Porpodis K, Boutou AK, et al. COVID-19 and liver injury: an ongoing challenge. World J Gastroenterol. 2023;29(2):257–71. https://doi.org/10.3748/wjg.v29.i2.257" }, { "DOI": "10.1016/j.biopha.2022.113568", "doi-asserted-by": "crossref", "key": "ref13", "unstructured": "Li P, Liu Y, Cheng Z, Yu X, Li Y. COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management. Biomed Pharmacother. 2022;154:113568. https://doi.org/10.1016/j.biopha.2022.113568" }, { "DOI": "10.3390/ijms23094828", "doi-asserted-by": "crossref", "key": "ref14", "unstructured": "Teschke R, Méndez-Sánchez N, Eickhoff A. Liver injury in COVID-19 patients with drugs as causatives: A systematic review of 996 DILI cases published 2020/2021 based on RUCAM as causality assessment method. Int J Mol Sci. 2022;23(9):4828. https://doi.org/10.3390/ijms23094828" }, { "DOI": "10.1111/liv.14516", "doi-asserted-by": "crossref", "key": "ref15", "unstructured": "Muhović D, Bojović J, Bulatović A, Vukčević B, Ratković M, Lazović R, et al. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19. Liver Int. 2020;40(8):1901–5. https://doi.org/10.1111/liv.14516" }, { "DOI": "10.19163/2307-9266-2022-10-3-267-277", "doi-asserted-by": "crossref", "key": "ref16", "unstructured": "Petrov VI, Ryazanova AYu, Privaltseva NS, Nekrasov DA. Polypharmacy in managment of in-patients with novel coronavirus disease (COVID-19). Pharmacy & Pharmacology. 2022;10(3):267–77 (In Russ.). https://doi.org/10.19163/2307-9266-2022-10-3-267-277" }, { "key": "ref17", "unstructured": "Grjibovski AM, Ivanov SV, Gorbatova MA. Case-control studies in healthcare. Science & Healthcare. 2015;(4):5–17 (In Russ.). EDN: VCFVUZ" } ], "reference-count": 17, "references-count": 17, "relation": {}, "resource": { "primary": { "URL": "https://www.risksafety.ru/jour/article/view/458" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "The Effect of Potentially Hepatotoxic Medicinal Products on Alanine Transaminase Levels in COVID-19 Patients: A Case–Control Study", "type": "journal-article", "update-policy": "https://doi.org/10.30895/2312-7821-crossmark" }